Osilodrostat-associated Adrenal Gland Shrinkage: A Case Series of Patients With ACTH-dependent Cushing's Syndrome
The Journal of Clinical Endocrinology & Metabolism · 17.03.2026 · 111 (4) · 1084-1090
DOI: 10.1210/clinem/dgaf552 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 07.10.2025. Verfasst von Elena V Varlamov und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (Division of Endocrinology, Diabetes and Clinical Nutrition) and Neurological Surgery and Pituitary Center, Oregon Health & Sc…. Hauptthemen laut MEDLINE: Cushing Syndrome, Adrenal Glands, Adrenocorticotropic Hormone, Adrenal Insufficiency. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Context
Medical therapy for Cushing's syndrome (CS) is increasingly used. A potent adrenal steroidogenesis inhibitor, osilodrostat, has been rarely linked to prolonged adrenal insufficiency (AI).
Objective
We hypothesized that osilodrostat-induced AI could be associated with adrenal gland shrinkage.
Design
Noninterventional, retrospective, longitudinal, institutional review board-approved study of patients with CS treated at Oregon Health and Science University between January 1, 2000, and July 1, 2025.
Setting
Ambulatory and inpatient, academic, quaternary medical center. Patients or Other Participants Patients with ACTH-dependent CS, treated with osilodrostat for >3 months, and computed tomography (CT) imaging before and after osilodrostat available for adrenal volume (AV) measurement. Intervention(s) Age, sex, osilodrostat doses and duration, laboratory data, and AI were recorded. AV was calculated using manual segmentation on CT images by a board-certified radiologist. Main Outcome Measure(s) AV before and after initiation of osilodrostat was expressed as percent reduction.
Results
Ten patients (5 ectopic CS, 4 unknown ACTH source, 1 Cushing's disease) were included. Osilodrostat mean starting, maximum, and final doses: 7.7, 13.8, and 5.9 mg/day, respectively, over 23 months. Four patients received block-and-replace regimen, AI developed in 5. Adrenal gland volume decreased by 46.7 ± 22.2% from 25.5 ± 9.9 mL to 12.7 ± 6.4 mL, P < .001 over a median of 19 months. AV reduction positively correlated with maximum osilodrostat dose, r = 0.626, P = .027.
Conclusion
We found that in selected patients with ACTH-dependent CS, osilodrostat can induce significant adrenal shrinkage, with or without AI. Further confirmation by larger studies of different CS types and monitoring for AI is required for all patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine (Division of Endocrinology, Diabetes and Clinical Nutrition) and Neurological Surgery and Pituitary Center, Oregon Health & Science University, Portland, OR 97239, USA.
- Dotter Department of Interventional Radiology, Oregon Health & Science University, Portland, OR 97239, USA.
ORCID-Profile: Elena V Varlamov, Maria Fleseriu
Zitieren
APA
Varlamov, E. V., Park, B. J., & Fleseriu, M. (2026). Osilodrostat-associated Adrenal Gland Shrinkage: A Case Series of Patients With ACTH-dependent Cushing's Syndrome. The Journal of Clinical Endocrinology & Metabolism, 111(4), 1084-1090. https://doi.org/10.1210/clinem/dgaf552
Vancouver
Varlamov EV, Park BJ, Fleseriu M. Osilodrostat-associated Adrenal Gland Shrinkage: A Case Series of Patients With ACTH-dependent Cushing's Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2026;111(4):1084-1090. doi:10.1210/clinem/dgaf552
BibTeX
@article{Varlamov2026,
author = {Varlamov, Elena V and Park, Brian J and Fleseriu, Maria},
title = {Osilodrostat-associated Adrenal Gland Shrinkage: A Case Series of Patients With ACTH-dependent Cushing's Syndrome},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {4},
pages = {1084--1090},
doi = {10.1210/clinem/dgaf552}
}
EUVIMED